Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 9:23 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2209–2232 of 2,742 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Neuroendocrine Tumours Clear all
Completed Not applicable Interventional

Safety and Efficacy of Silicone Oil Tamponade for Surgical Attenuation of Radiation Damage in Choroidal Melanoma

NCT01460810
View directory record Official record
Conditions
Choroidal Melanoma
Interventions
1000CsK Silicon Oil Tamponade
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 7, 2022 · Synced Nov 3, 2026, 9:23 PM EST
Terminated Phase 2 Interventional Results available

Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement

NCT04221438
View directory record Official record
Conditions
Melanoma of Unknown Primary, Metastatic Malignant Neoplasm in Lymph Node, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Recurrent Cutaneous Melanoma
Interventions
Binimetinib, Conventional Surgery, Encorafenib, Fluorothymidine F-18
Drug · Procedure · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
10
States / cities
Los Angeles, California • Ann Arbor, Michigan • City of Saint Peters, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Nov 3, 2026, 9:23 PM EST
Recruiting Not applicable Interventional

High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies

NCT05053555
View directory record Official record
Conditions
Liver Malignant Tumors, Cholangiocarcinoma Metastatic, Pancreatic Cancer, Melanoma
Interventions
high dose rate brachytherapy
Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
19 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Nov 3, 2026, 9:23 PM EST
Completed Phase 1 Interventional

Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab

NCT02935790
View directory record Official record
Conditions
Malignant Melanoma
Interventions
ACY-241, nivolumab, ipilimumab
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 24, 2017 · Synced Nov 3, 2026, 9:23 PM EST
Recruiting Phase 1 Interventional

A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma

NCT05607095
View directory record Official record
Conditions
Uveal Melanoma, Melanoma, Metastatic Uveal Melanoma, Metastatic Melanoma
Interventions
Lifileucel (LN-144/LN-145)
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Harrison, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Nov 3, 2026, 9:23 PM EST
Terminated Phase 2 Interventional Results available

A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma

NCT03301636
View directory record Official record
Conditions
Melanoma
Interventions
Pembrolizumab, Nivolumab, Indoximod
Drug
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
4
States / cities
Iowa City, Iowa • Rochester, Minnesota • Albuquerque, New Mexico + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Nov 3, 2026, 9:23 PM EST
Completed Phase 2 Interventional

Phase II, 2nd Line Melanoma - RAND Monotherapy

NCT00612664
View directory record Official record
Conditions
Melanoma
Interventions
Anti-CD137 (4-1BB) (BMS-663513)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
10
States / cities
Los Angeles, California • New Haven, Connecticut • Park Ridge, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Nov 3, 2026, 9:23 PM EST
Terminated Phase 1 Interventional Results available

NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma

NCT01810016
View directory record Official record
Conditions
Unresectable or Metastatic Melanoma
Interventions
Ipilimumab, NY-ESO-1 Protein Vaccine, NY-ESO-1 OLP4 Vaccine with Poly-ICLC and Montanide, NY-ESO-1 OLP4 Vaccine with Poly-ICLC
Biological
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
4
States / cities
New York, New York • Pittsburgh, Pennsylvania • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Nov 3, 2026, 9:23 PM EST
Enrolling by invitation No phase listed Observational

A Long-Term Follow-Up Study of Subjects Completing the AU-011-301(CoMpass) for Early Choroidal Melanoma

NCT07338968
View directory record Official record
Conditions
Choroidal Melanoma, Indeterminate Lesions
Interventions
Observational
Other
Lead sponsor
Aura Biosciences
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
10
States / cities
Sacramento, California • Ann Arbor, Michigan • Rochester, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Nov 3, 2026, 9:23 PM EST
Recruiting Phase 1 Interventional

A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors

NCT05746897
View directory record Official record
Conditions
Ovarian Cancer, Melanoma, Triple Negative Breast Cancer, Colorectal Cancer
Interventions
NM1F Injection, Pembrolizumab injection
Drug
Lead sponsor
Hefei TG ImmunoPharma Co., Ltd.
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Dallas, Texas • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 26, 2024 · Synced Nov 3, 2026, 9:23 PM EST
Terminated Phase 2 Interventional Results available

Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma

NCT04955743
View directory record Official record
Conditions
Melanoma, Renal Cell Carcinoma, Brain Metastases, PD1/PD-L1 Experienced, Pembrolizumab, Lenvatinib, Metastatic Melanoma
Interventions
Pembrolizumab, Lenvatinib
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Nov 3, 2026, 9:23 PM EST
Terminated Phase 3 Interventional Results available

Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma

NCT02263508
View directory record Official record
Conditions
Melanoma
Interventions
Talimogene Laherparepvec, Pembrolizumab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 95 Years
Enrollment
713 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
41
States / cities
Birmingham, Alabama • Mobile, Alabama • Beverly Hills, California + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Nov 3, 2026, 9:23 PM EST
Completed Phase 1 Interventional

Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma

NCT00356460
View directory record Official record
Conditions
Carcinoma, Renal Cell, Melanoma
Interventions
GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody
Biological
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
6
States / cities
Bethesda, Maryland • Boston, Massachusetts • Cambridge, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2014 · Synced Nov 3, 2026, 9:23 PM EST
Completed Phase 1 Interventional

Study of DF6215 in Patients With Advanced Solid Tumors

NCT06108479
View directory record Official record
Conditions
Solid Tumor, Adult, Solid Tumor Cancer
Interventions
DF6215, pembrolizumab, KEYTRUDA®
Drug
Lead sponsor
Dragonfly Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
9
States / cities
Los Angeles, California • Orange, California • San Diego, California + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Nov 3, 2026, 9:23 PM EST
Completed Phase 2 Interventional Results available

Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer

NCT00118248
View directory record Official record
Conditions
Recurrent Thyroid Cancer, Stage IV Follicular Thyroid Cancer, Stage IV Papillary Thyroid Cancer, Thyroid Gland Medullary Carcinoma
Interventions
tanespimycin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 15, 2017 · Synced Nov 3, 2026, 9:23 PM EST
Active, not recruiting Phase 1 Interventional

Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy

NCT06736418
View directory record Official record
Conditions
Small-Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Carcinoma of the Lung
Interventions
225Ac-ABD147
Drug
Lead sponsor
Abdera Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
12
States / cities
Newport Beach, California • San Francisco, California • Santa Monica, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Nov 3, 2026, 9:23 PM EST
Completed Phase 1 Interventional

A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State

NCT02608034
View directory record Official record
Conditions
Metastatic Melanoma, BRAF V600 Mutation Positive
Interventions
Itraconazole, Rifampin, Vemurafenib
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2020 · Synced Nov 3, 2026, 9:23 PM EST
Not listed Phase 1 Interventional

Immunotherapy Study of Evofosfamide in Combination With Ipilimumab

NCT03098160
View directory record Official record
Conditions
Pancreatic Cancer, Melanoma, Squamous Cell Carcinoma of the Head and Neck, Prostate Cancer
Interventions
Evofosfamide, Ipilimumab
Drug
Lead sponsor
Threshold Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2017 · Synced Nov 3, 2026, 9:23 PM EST
Recruiting Not applicable Interventional

MySmartSkin Online Skin Self-exam Intervention for Melanoma Survivors

NCT05373823
View directory record Official record
Conditions
Melanoma
Interventions
MySmartSkin enhancement, Educational webpage on Skin Self-Examination, Assess implementation outcomes
Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Nov 3, 2026, 9:23 PM EST
Completed No phase listed Observational

Analysis of NF2 Mutations in Radiation-Related Neural Tumors

NCT00340496
View directory record Official record
Conditions
Neural Tumors
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Nov 3, 2026, 9:23 PM EST
Completed Phase 1 Interventional

Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers

NCT02639026
View directory record Official record
Conditions
Metastatic, Melanoma, Non Small Cell Lung Cancer (NSCLC), Breast Cancer, Pancreatic Cancer
Interventions
Radiotherapy, MEDI4736, Tremelimumab
Radiation · Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Nov 3, 2026, 9:23 PM EST
Recruiting Phase 2 Interventional

A Study of IBI363 in Subjects with Advanced Solid Malignancies

NCT06281678
View directory record Official record
Conditions
Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer, Renal Cell Cancer
Interventions
IBI363
Drug
Lead sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Industry
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
9
States / cities
San Francisco, California • Ocala, Florida • Plantation, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Nov 3, 2026, 9:23 PM EST
Terminated Phase 1 Interventional

A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.

NCT02601378
View directory record Official record
Conditions
Uveal Melanoma
Interventions
LXS196, LXS196 and HDM201
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 29, 2022 · Synced Nov 3, 2026, 9:23 PM EST
Not listed Phase 1 Interventional

Bleomycin With or Without Electroporation Therapy in Treating Patients With Stage III or Stage IV Melanoma

NCT00006035
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
bleomycin sulfate, electroporation therapy
Biological · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 17, 2013 · Synced Nov 3, 2026, 9:23 PM EST